PMID- 10860577 OWN - NLM STAT- MEDLINE DCOM- 20000830 LR - 20181113 IS - 1044-7431 (Print) IS - 1095-9327 (Electronic) IS - 1044-7431 (Linking) VI - 15 IP - 6 DP - 2000 Jun TI - HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosis. PG - 495-509 AB - The importance of genetic susceptibility in determining the progression of demyelination and neurologic deficits is a major focus in neuroscience. We studied the influence of human leukocyte antigen (HLA)-DQ polymorphisms on disease course and neurologic impairment in virus-induced demyelination. HLA-DQ6 or DQ8 was inserted as a transgene into mice lacking endogenous expression of MHC class I (beta(2)m) and class II (H2-A(beta)) molecules. Following Theiler's murine encephalomyelitis virus (TMEV) infection, we assessed survival, virus persistence, demyelination, and clinical disease. Mice lacking expression of endogenous class I and class II molecules (beta(2)m(o) Abeta(o) mice) died 3 to 4 weeks postinfection (p.i.) due to overwhelming virus replication in neurons. beta(2)m(o) Abeta(o) DQ6 and beta(2)m(o) Abeta(o) DQ8 mice had increased survival and decreased gray matter disease and virus replication compared to nontransgenic littermate controls. Both beta(2)m(o) Abeta(o) DQ6 and beta(2)m(o) Abeta(o) DQ8 mice developed chronic virus persistence in glial cells of the white matter of the spinal cord, with greater numbers of virus antigen-positive cells in beta(2)m(o) Abeta(o) DQ8 than in beta(2)m(o) Abeta(o) DQ6 mice. At day 45 p.i., the demyelinating lesions in the spinal cord of beta(2)m(o) Abeta(o) DQ8 were larger than those in the beta(2)m(o) Abeta(o) DQ6 mice. Earlier and more profound neurologic deficits were observed in beta(2)m(o) Abeta (o) DQ8 mice compared to beta(2)m(o) Abeta(o) DQ6 mice, although by 120 days p.i. both strains of mice showed similar extent of demyelination and neurologic deficits. Delayed-type hypersensitivity and antibody responses to TMEV demonstrated that the mice mounted class II-mediated cellular and humoral immune responses. The results are consistent with the hypothesis that rates of progression of demyelination and neurologic deficits are related to the differential ability of DQ6 and DQ8 transgenes to modulate the immune response and control virus. CI - Copyright 2000 Academic Press. FAU - Pavelko, K D AU - Pavelko KD AD - Department of Immunology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905, USA. FAU - Drescher, K M AU - Drescher KM FAU - McGavern, D B AU - McGavern DB FAU - David, C S AU - David CS FAU - Rodriguez, M AU - Rodriguez M LA - eng GR - R01 NS032129/NS/NINDS NIH HHS/United States GR - R37 AI014764/AI/NIAID NIH HHS/United States GR - R01 AI014764/AI/NIAID NIH HHS/United States GR - F31 MH012120/MH/NIMH NIH HHS/United States GR - NS 32129/NS/NINDS NIH HHS/United States GR - AI14764/AI/NIAID NIH HHS/United States GR - NS 24180/NS/NINDS NIH HHS/United States GR - R01 NS024180/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Mol Cell Neurosci JT - Molecular and cellular neurosciences JID - 9100095 RN - 0 (Antigens, Viral) RN - 0 (HLA-DQ Antigens) SB - IM MH - Acute Disease MH - Animals MH - Antibody Formation/genetics MH - Antigens, Viral/analysis MH - Brain/immunology/virology MH - Cardiovirus Infections/*genetics/immunology/mortality MH - Chronic Disease MH - Demyelinating Diseases/genetics/immunology MH - Disease Models, Animal MH - Disease Progression MH - Genetic Predisposition to Disease MH - HLA-DQ Antigens/*genetics MH - Humans MH - Hypersensitivity, Delayed/immunology/virology MH - Mice MH - Mice, Inbred C57BL MH - Mice, Transgenic MH - Motor Activity MH - Multiple Sclerosis/*genetics/immunology MH - Nerve Fibers/immunology/virology MH - *Polymorphism, Genetic MH - Postural Balance MH - Spinal Cord/immunology/virology MH - Survival Analysis MH - *Theilovirus MH - Virus Replication/immunology PMC - PMC5450945 MID - NIHMS859410 EDAT- 2000/06/22 10:00 MHDA- 2000/09/02 11:01 PMCR- 2017/05/31 CRDT- 2000/06/22 10:00 PHST- 2000/06/22 10:00 [pubmed] PHST- 2000/09/02 11:01 [medline] PHST- 2000/06/22 10:00 [entrez] PHST- 2017/05/31 00:00 [pmc-release] AID - S1044-7431(00)90843-1 [pii] AID - 10.1006/mcne.2000.0843 [doi] PST - ppublish SO - Mol Cell Neurosci. 2000 Jun;15(6):495-509. doi: 10.1006/mcne.2000.0843.